CT-P10

BIOLOGICAL3 trials

Sponsors

Celltrion

Conditions

Follicular LymphomaLymphoma, FollicularRheumatoid Arthritis

Phase 3

PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis

CompletedNCT02149121

CelltrionRheumatoid Arthritis

Start: 2014-08-31End: 2017-01-31Updated: 2021-12-16

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

CompletedNCT02162771

CelltrionLymphoma, Follicular

Start: 2014-07-14End: 2018-12-29Updated: 2020-01-29

To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma

CompletedNCT02260804

CelltrionFollicular Lymphoma

Start: 2015-11-09End: 2019-09-04Updated: 2021-04-08

Related Papers

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study

Blood Advances2021-09-038 citations

Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study.

2021-08-288 citations

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Blood2019-11-133 citations

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

Lara D. Veeken2019-04-0644 citations

Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.

2019-02-0117 citations

Similar Efficacy and Safety of CT-P10 and Reference Rituximab in Patients with Advanced Stage Follicular Lymphoma: Updated Phase III Study Results

Blood2018-11-294 citations

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

Blood2018-11-292 citations

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.

2018-11-0143 citations

Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial

mAbs2018-07-1652 citations

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.

2017-08-0131 citations

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.

2017-07-1451 citations

A DOUBLE‐BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT‐P10 TO RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH ADVANCED‐STAGE FOLLICULAR LYMPHOMA

Hematological Oncology2017-06-013 citations

Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma.

Journal of Clinical Oncology2017-05-205 citations

Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

Blood2016-12-0213 citations

Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL)

Blood2015-12-035 citations